Asset profile

ziftomenib · Kura Oncology (KURA)

Indication: relapsed or refractory NPM1-mutated AML
Also known as: KOMZIFTI

Company

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncol…

Start live analysis of KURA Run 8-agent AI analysis

On the calendar

Nov 2025

Nov 30, 2025

335 days ago

KURAKura Oncology

Kura Oncology: ziftomenib PDUFA set for Nov 30, 2025 (R/R NPM1-m AML)

FDA decision (PDUFA)Outcome not recordedSEC 8-K

Quarter only

~ Quarter only

KURAKura Oncology

Kura Oncology reports 2Q 2026 financials; KOMZIFTI $9.1M revenue

Conference presentationOutcome not recordedSEC 8-KQuarter only

Mar 2027

~ Mar 2027

KURAKura Oncology

ziftomenib: Phase 2 trial NCT07623616 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Dec 2027

Dec 31, 2027

in 426 days

KURAKura Oncology

ziftomenib: Phase 2 trial NCT06930352 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Oct 2028

Oct 16, 2028

in 716 days

KURAKura Oncology

ziftomenib: Phase 1/Phase 2 trial NCT04067336 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Dec 2028

~ Dec 2028

KURAKura Oncology

ziftomenib: Phase 1/Phase 2 trial NCT05848687 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Nov 2031

~ Nov 2031

KURAKura Oncology

ziftomenib: Phase 3 trial NCT07007312 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Timeline

Newest first.

Oct 13, 2026

03:20 PM

KURAKura Oncology

ziftomenib · NCT07007312 registry update

Trial registry changeClinicalTrials.gov

Oct 7, 2026

03:21 PM

KURAKura Oncology

ziftomenib · NCT07007312 registry update

Trial registry changeClinicalTrials.gov

Aug 12, 2026

08:10 PM

KURAKura Oncology

Kura Oncology reports 2Q 2026 financials; KOMZIFTI $9.1M revenue

Conference presentationSEC 8-K

Nov 4, 2025

11:35 AM

KURAKura Oncology

Kura Oncology: ziftomenib PDUFA set for Nov 30, 2025 (R/R NPM1-m AML)

PDUFA date setSEC 8-K Open record

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT04067336	Phase 1/2	Active, not recruiting	Oct 16, 2028	263	20 of 43 sites in the United States
NCT07007312	Phase 3	Recruiting	Nov 1, 2031	1300	44 of 136 sites in the United States
NCT05848687	Phase 1/2	Recruiting	Dec 1, 2028	90	17 of 24 sites in the United States
NCT07623616	Phase 2	Recruiting	Mar 1, 2027	6	0 of 20 sites in the United States
NCT06930352	Phase 2	Recruiting	Dec 31, 2027	70	1 of 1 sites in the United States